The Latest Cardiac and Vascular News
TEL AVIV, Israel, April 19, 2021 /PRNewswire/ — Vaica™ Medical, an innovation leading provider in medication adherence and remote patient management (RPM) is announcing its anti-coagulation (blood clotting) remote management solution. The need to maintain an optimal blood viscosity levels is pertinent for at-risk patients with Thrombotic Predisposition (hypercoagulable states), heart rhythm disorders, […]
VANCOUVER and MINNEAPOLIS, April 19, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the journal EuroIntervention has published an article entitled, “Coronary Sinus Reducer Implantation Results in Improved Oxygen Kinetics at Cardiopulmonary Exercise Test in Patients with Refractory Angina.” The article, authored by Carlo Zivelonghi, M.D., Antwerp […]
300th patient randomized in ANTHEM-HFrEF pivotal study LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has randomized the 300th patient in the Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure With Reduced Ejection Fraction (ANTHEM-HFrEF) Pivotal Study, which was approved by the U.S. Food and Drug Administration (FDA) […]
Elucid Software Quantifies Plaque Morphology to Enable Better Assessment of IPE Treatment Effects BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular disease, announced that first author and Elucid founder Andrew Buckler presented findings today from the […]
VANCOUVER and MINNEAPOLIS, April 16, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today announced that the Tiara Transapical system (“Tiara TA”) will be unable to receive a European CE mark under the current Medical Device Directive regulations (“MDD”) ending on May 26, 2021. The Company is […]
MINNEAPOLIS, April 16, 2021 /PRNewswire/ — Seigla Medical, Inc., announced conformité européenne (CE) Mark for the company’s LiquID™ Guide Catheter Extension for use in coronary and peripheral vasculature interventions. Guide catheter extensions are a crucial tool used by cardiologists worldwide to assist in the delivery of stents and other interventional devices. In addition, […]
Study evaluates safety and performance of endovascular pulmonary neuromodulation in ADHF MINNEAPOLIS, April 15, 2021 /PRNewswire/ — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce initial enrollment in their Cardionomic Pulmonary Neuromodulation System (CPNS) Pilot Study. The study will evaluate the safety and performance of the CPNS in patients suffering from Acute […]
Silence Therapeutics Announces Publication in Cardiovascular Research Highlighting the Emerging Potential of RNA Therapeutics in Preventing Lipoprotein(a)-Mediated Cardiovascular Disease –High Lipoprotein(a) is a genetically determined cardiovascular risk factor affecting around 20% of the world’s population 15 April 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (“Silence” or “the Company”), […]
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (NASDAQ:ABMD) announced today that the first patient has been enrolled in PROTECT IV, a large, prospective, multi-center randomized controlled trial (RCT) that is designed to provide the level of clinical evidence needed to achieve a Class I guideline recommendation for Impella in high-risk percutaneous coronary intervention (HRPCI). The first patient […]
BALTIMORE–(BUSINESS WIRE)–NeoProgen, Inc., a pre-clinical stage company developing an exosome-based product from human neonatal heart-derived Medicinal Signaling Cells (nMSCs) for tissue repair and regeneration for the treatment of heart failure (HF) and other inflammatory diseases, announced that it has received a patent from the United States Patent Office Patent No.: […]
